These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 12665120)
1. Buprenorphine TDS: use in daily practice, benefits for patients. Radbruch L Int J Clin Pract Suppl; 2003 Feb; (133):19-22; discussion 23-4. PubMed ID: 12665120 [TBL] [Abstract][Full Text] [Related]
2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
3. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients. Griessinger N; Sittl R; Likar R Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522 [TBL] [Abstract][Full Text] [Related]
4. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Sorge J; Sittl R Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693 [TBL] [Abstract][Full Text] [Related]
5. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison. Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542 [TBL] [Abstract][Full Text] [Related]
6. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. Sittl R; Nuijten M; Nautrup BP Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study. Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818 [TBL] [Abstract][Full Text] [Related]
8. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Likar R; Kayser H; Sittl R Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176 [TBL] [Abstract][Full Text] [Related]
9. [The transdermal 7-day buprenorphine patch--an effective and safe treatment option, if tramadol or tilidate/naloxone is insufficient. Results of a non-interventional study]. Schutter U; Ritzdorf I; Heckes B MMW Fortschr Med; 2010 Jul; 152 Suppl 2():62-9. PubMed ID: 21591321 [TBL] [Abstract][Full Text] [Related]
10. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Sittl R; Likar R; Nautrup BP Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486 [TBL] [Abstract][Full Text] [Related]
11. Buprenorphine TDS: the clinical development rationale and results. Radbruch L; Vielvoye-Kerkmeer A Int J Clin Pract Suppl; 2003 Feb; (133):15-8; discussion 23-4. PubMed ID: 12665119 [TBL] [Abstract][Full Text] [Related]
12. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Pergolizzi JV; Mercadante S; Echaburu AV; Van den Eynden B; Fragoso RM; Mordarski S; Lybaert W; Beniak J; Orońska A; Slama O; Curr Med Res Opin; 2009 Jun; 25(6):1517-28. PubMed ID: 19435402 [TBL] [Abstract][Full Text] [Related]
13. Transdermal buprenorphine in cancer pain and palliative care. Sittl R Palliat Med; 2006; 20 Suppl 1():s25-30. PubMed ID: 16764218 [TBL] [Abstract][Full Text] [Related]
14. [Post marketing surveillance study with an analgesic (transdermal buprenorphine patch) in patients with moderate to severe chronic pain]. Tschirner M; Ritzdorf I; Brünjes R MMW Fortschr Med; 2008 Sep; 150 Suppl 3():142-8. PubMed ID: 19025217 [TBL] [Abstract][Full Text] [Related]
15. Buprenorphine and the transdermal system: the ideal match in pain management. Budd K Int J Clin Pract Suppl; 2003 Feb; (133):9-14; discussion 23-4. PubMed ID: 12665118 [TBL] [Abstract][Full Text] [Related]
16. Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: results from the Cancer Pain Outcome Research (CPOR) Study Group. Apolone G; Corli O; Negri E; Mangano S; Montanari M; Greco MT; ; Apolone G; Bertetto O; Caraceni A; Corli O; De Conno F; Labianca R; Maltoni M; Nicora Maria F; Torri V; Zucco F Clin J Pain; 2009 Oct; 25(8):671-82. PubMed ID: 19920716 [TBL] [Abstract][Full Text] [Related]
17. Transdermal buprenorphine in pain management--experiences from clinical practice: Five case studies. Louis F Int J Clin Pract; 2006 Oct; 60(10):1330-4. PubMed ID: 16981980 [TBL] [Abstract][Full Text] [Related]
18. Transdermal buprenorphine in the treatment of chronic pain. Sittl R Expert Rev Neurother; 2005 May; 5(3):315-23. PubMed ID: 15938664 [TBL] [Abstract][Full Text] [Related]
19. High dose transdermal buprenorphine for moderate to severe pain in spanish pain centres--a retrospective multicenter safety and efficacy study. Barutell C; Camba A; González-Escalada JR; Rodríguez M; Pain Pract; 2008; 8(5):355-61. PubMed ID: 18662364 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain. Poulain P; Denier W; Douma J; Hoerauf K; Samija M; Sopata M; Wolfram G J Pain Symptom Manage; 2008 Aug; 36(2):117-25. PubMed ID: 18411010 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]